Archive | October, 2009
Vertex Hep C Competitor (NASDAQ:VRTX)
Competition in the biotech sector is always cut-throat and that is what makes this sector more dynamic than any other as the faith of the company lies directly in the hands of the researchers that come out with life saving drugs that can sweep the market by storm. Currently the hepatitis C drug called telaprevir [...]
Continue reading...AVI BioPharma’s Expansion Plans (NASDAQ:AVII)
6 October 2009 – 7:30 am PDT
Comments Off
AVI BioPharma have recently announced that they have received a funding for expansion plans of their Junin virus drug treatment. Soon after the annoucement was made, AVI BioPharma stocks were trading higher on a surge in volume. AVI BioPharma has announced that they have received expanded contract of approximately US$ 11.5 million from the Defense [...]
Continue reading...Depomed’s New Shingle Drug (NASDAQ:DEPO)
6 October 2009 – 7:00 am PDT
Comments Off
On the very first day of the week, Depomed Inc has come out with good news that their new shingles pain drug has met the study goal. Depomed has announced that they have achieved success in the late stage clinical trial of a drug that will be used for the treatment of pain following viral [...]
Continue reading...Shares of Amicus Drop (NASDAQ:FOLD)
6 October 2009 – 6:30 am PDT
Comments Off
It was a downward slide for the Amicus Therapeutics on Monday when the drug company announced the failure of its drug candidate for Gaucher disease, an enzyme disorder. The shares of Amicus Therapeutics dropped considerably soon after the company came out with the disappointing news about the inefficiency of their drug named Plicera. The shares [...]
Continue reading...Enzon drug Gets FDA Approval (NASDAQ:ENZN)
6 October 2009 – 6:00 am PDT
Comments Off
On a Monday afternoon, Enzon Pharmaceuticals made an announcement that FDA Oncologic Drug Advisory Committee has voted in the favor of and has approved the use of Pegintron as a treatment in addition to surgery in patients with metastatic melanoma. The news of FDA approval has boosted Enzon Pharmaceuticals and even the shares of the [...]
Continue reading...Trimeris New Agreement (NASDAQ:TRMS)
5 October 2009 – 7:30 am PDT
Comments Off
Trimeris Inc today has announced that they have entered into a definitive merger agreement with the Korean corporation, Arigene Co. Ltd., which is currently trading on the Korean Securities Dealer Association Quotation System. Trimeris Inc is a biopharmaceutical company that is currently engaged in the commercialization of therapeutic agents of viral diseases. They are well [...]
Continue reading...Dapagliflozin meets endpoints (NYSE:BMY)
5 October 2009 – 7:00 am PDT
Comments Off
It was announced today that Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca’s diabetes drug dapagliflozin has successfully met the endpoints in the first phase III study. The companies together stated that their diabetes drug was able to meet both primary and secondary endpoints in the first phase trial successfully. The result from the 24 weeks clinical study [...]
Continue reading...Bionovo’s New Offering (NASDAQ:BNVI)
5 October 2009 – 6:30 am PDT
Comments Off
Bionovo Inc that have always focused on developing treatments for women’s health and breast cancer announced that they might raise around US$ 20 million in gross proceeds from an offering of up to 3.2 million units priced at $6.20 per unit. Each unit consists of ten shares of common stock and ten warrants and each [...]
Continue reading...Allergan sues FDA (NYSE:AGN)
5 October 2009 – 6:00 am PDT
Comments Off
One of the well known makers of the Botox wrinkle treatment, Allergan Inc, has gathered its courage and challenged the government’s ban on off-label drug marketing to doctors. The company challenges this idea by the FDA saying that it violates the company’s right to freedom of speech. The company has clearly stated in its lawsuit [...]
Continue reading...BioCryst clarifies government declaration (NASDAQ:BCRX)
5 October 2009 – 5:30 am PDT
Comments Off
BioCryst Pharmaceuticals have clarified today that the Government Declaration about their antiviral Peramivir requires a step before they can issue an Emergency Use Authorization or EUA. The company announced that the Office of the Secretary, Department of Health and Human Services (HHS) has issued “HHS Secretary’s Declaration for the Use of the Public Readiness and [...]
Continue reading...
6 October 2009 – 8:00 am PDT
Comments Off